- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00931281
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
October 11, 2010 updated by: Abbott
A Blinded, Randomized, Nonfasting, Placebo-Controlled Study in Healthy Adults to Evaluate Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Ascending Doses of ABT-450 With Ritonavir
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of multiple doses of an experimental hepatitis C virus (HCV) protease inhibitor with ritonavir in healthy volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multiple ascending dose, non-fasting, open label, randomized study.
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Waukegan, Illinois, United States, 60085
- Site Reference ID/Investigator# 18161
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- overall healthy subjects
- non-childbearing potential females included
Exclusion Criteria:
- history of significant sensitivity to any drug
- positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab
- history of gastrointestinal issues or procedures
- history of seizures, diabetes or cancer (except basal cell carcinoma)
- clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder
- use of tobacco or nicotine-containing products within the 6-month period prior to study drug administration
- donation or loss of 550mL or more blood volume or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration
- abnormal screening laboratory results that are considered clinically significant by the investigator
- current enrollment in another clinical study
- previous enrollment in this study
- recent (6-month) history of drug/alcohol abuse that could preclude adherence to the protocol
- pregnant or breastfeeding female
- requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
ABT-450/ritonavir
|
capsules, QD or BID, 14 days, ascending doses
capsules, QD or BID, 14 days, ascending doses
Other Names:
|
Placebo Comparator: 2
Placebo for ABT-450/placebo for ritonavir
|
capsule, QD or BID, 14 days
Other Names:
capsule, QD or BID, 14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics (blood draws, pre- and post-dose)
Time Frame: 17 days
|
17 days
|
Safety and Tolerability (ECGs, AEs, vitals, physical exams, routine labs)
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Isabelle A Gaultier, M.S., IBMH, Abbott
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
June 5, 2009
First Submitted That Met QC Criteria
June 30, 2009
First Posted (Estimate)
July 2, 2009
Study Record Updates
Last Update Posted (Estimate)
October 13, 2010
Last Update Submitted That Met QC Criteria
October 11, 2010
Last Verified
September 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis
- Hepatitis C
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
Other Study ID Numbers
- M10-861
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCV Infection
-
Valme University HospitalBoehringer IngelheimUnknown
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Sunshine Lake Pharma Co., Ltd.Recruiting
-
Gilead SciencesCompletedChronic HCV InfectionChina, Hong Kong, Taiwan, Korea, Republic of, Vietnam
-
Assiut UniversityUnknown
-
Fundacion para la Investigacion Biomedica del Hospital...Instituto de Salud Carlos IIICompletedHIV Infection | HCV CoinfectionSpain
-
Gilead SciencesCompletedChronic HCV InfectionChina, Korea, Republic of, Taiwan
-
Gilead SciencesCompleted
-
Naomi LubanNational Heart, Lung, and Blood Institute (NHLBI)CompletedTransfusion-induced HCV and HGV Infection
Clinical Trials on ABT-450
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C Infection
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C Infection
-
AbbVie (prior sponsor, Abbott)Completed
-
AbbVieCompleted
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
-
AbbVieCompletedChronic Hepatitis C Infection
-
AbbVie (prior sponsor, Abbott)Completed
-
AbbVie (prior sponsor, Abbott)Completed
-
AbbVieCompletedHepatitis C Virus | Hepatitis C Infection
-
AbbVie (prior sponsor, Abbott)CompletedCompensated Cirrhosis | Chronic Hepatitis C Infection